Fortrea Strategy and Business Model

Executive Overview

Fortrea is a global contract research organization (CRO) focused on helping pharmaceutical, biotechnology, and medical device companies design, run, and support clinical trials. Headquartered in Durham, North Carolina, Fortrea became an independent public company in 2023 when Labcorp separated its clinical development business. The company’s roots are older than the spin: its operating heritage comes from the Covance and Labcorp drug-development platform, which gives Fortrea established capabilities across Phase I through Phase IV clinical development. In practice, customers hire Fortrea to manage studies, provide embedded functional teams, run early-phase clinical pharmacology work, and deliver specialist services such as biometrics, safety, regulatory support, and patient recruitment support. Fortrea’s footprint spans North America, Europe, Asia-Pacific, and other major research markets, which is essential because many modern trials are multi-country and highly regulated. In FY2024, Fortrea reported revenue of #N/A. Strategically, Fortrea is balancing two priorities at once: competing in a crowded global CRO market through execution and therapeutic expertise, while also completing the operational and financial transition from a carve-out into a standalone company with stronger margins, cleaner systems, and better cash generation.

Fortrea at a Glance

Logo
Common name	Fortrea
Full legal name	Fortrea Holdings Inc.
Headquarters	Durham, North Carolina, United States
Ownership	Public company; widely held shareholder base following the 2023 spin-off from Labcorp
Ticker	FTRE
Exchange	NASDAQ
Market Cap	$1.56B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Independent company since 2023; spun out of Labcorp’s clinical development business; operating roots trace to the Covance/Labcorp clinical development platform
Industry or industries	Contract research organization (CRO); outsourced clinical development services
Key products or services	Phase I-IV clinical development, clinical pharmacology, Functional Service Provider (FSP) solutions, biometrics, safety and regulatory support, patient recruitment support, medical device and diagnostics trial support
Geographic footprint	Global; North America, Europe, Asia-Pacific, Latin America, and other major clinical research markets
Business segments as officially reported	One operating and reportable segment
Company website	https://www.fortrea.com

1. What Is the Strategy of Fortrea?

Fortrea’s public strategy is best understood as the strategy of a newly independent, pure-play CRO: compete for outsourced clinical-development work where global delivery, therapeutic depth, and execution reliability matter, while improving profitability and cash generation as a standalone company after the Labcorp separation. Using the Playing to Win framework, the strategy looks like this.

1a. What is the winning aspiration of Fortrea?

Fortrea’s winning aspiration is to be a trusted global development partner for biopharma and med-tech sponsors across the clinical-trial lifecycle, while proving that it can operate successfully as an independent CRO. In public-company terms, “winning” appears to mean more than just revenue growth. It also means improving the quality of bookings, delivering studies predictably, restoring margins after the carve-out, and generating stronger cash flow. Since the 2023 spin, management communications have emphasized operational execution, customer fit, and financial improvement more than broad market-share rhetoric. That suggests a practical aspiration: become a focused, higher-quality, more profitable CRO rather than simply a larger one.
1b. Where does Fortrea play?

Fortrea plays in outsourced clinical development for pharmaceutical, biotechnology, and medical device companies. Its field of play includes Phase I through Phase IV work, full-service clinical trial execution, Functional Service Provider arrangements, early-phase clinical pharmacology, and related specialist capabilities such as biometrics, safety, and regulatory support. Geographically, it plays in global and multi-region studies rather than only local or single-country work. Just as important, Fortrea no longer plays as an integrated diagnostics-and-development company in the way Labcorp once did; after the spin, it is a focused clinical-development services company, not a central-labs-led conglomerate.
1c. How does Fortrea plan to win?

Fortrea appears to plan to win through differentiation, not pure cost leadership. The core recipe is a mix of global reach, end-to-end clinical-delivery capability, therapeutic and regulatory expertise, and long-standing sponsor relationships inherited from the legacy Covance/Labcorp platform. Since becoming independent, another part of the “how to win” has been tighter commercial discipline: pursuing work that fits Fortrea’s capabilities and return thresholds, improving delivery consistency, and reducing the drag of stranded spin costs and transitional complexity. In other words, Fortrea is trying to win by being a more focused and better-executing CRO, not merely by being cheap.
1d. What capabilities must Fortrea have in place?

To execute that strategy, Fortrea needs strong capabilities in global clinical operations, study start-up, site management, patient recruitment support, biometrics, data management, biostatistics, pharmacovigilance, medical writing, and regulatory support. It also needs specialized early-phase clinical pharmacology capabilities and the ability to provide embedded functional teams under FSP models. Since the spin, standalone corporate capabilities have also become strategically important: Fortrea must have its own finance, HR, procurement, quality, compliance, cybersecurity, and enterprise systems. For a CRO, operational capability and corporate infrastructure are tightly linked; if either side is weak, delivery quality and margins both suffer.
1e. What management systems does Fortrea require?

Fortrea requires management systems that keep a service business under tight operational control. That includes backlog and pipeline review, proposal governance, resource planning, billable-staff utilization tracking, project-level profitability management, change-order discipline, quality and compliance metrics, and cash-collection oversight. As a post-spin company, it also needs strong transition management: program offices, system migration plans, and governance for exiting transition-service arrangements with Labcorp. In a CRO, strategy lives or dies through staffing, study execution, customer satisfaction, and cash conversion, so the relevant management systems are operational as much as financial.

2. What Are the Current Strategic Initiatives of Fortrea?

Fortrea’s most visible strategic initiatives in FY2024 and subsequent public commentary were unusually concrete because the company was still early in life as a standalone public company. The major initiatives appear to be the following.

Complete the separation from Labcorp.One of Fortrea’s central initiatives has been standing up the systems, processes, and teams required to operate independently. That includes reducing reliance on transition-service arrangements and building or migrating core capabilities across finance, HR, procurement, IT, legal, compliance, and quality. This is not back-office housekeeping; it directly affects cost structure, managerial control, and customer service.
Restore profitability through productivity and cost discipline.Public disclosures have pointed to margin recovery as a major priority. In practice, that means simplifying the organization, improving billable utilization, managing overhead that came with the separation, and tightening delivery processes. For Fortrea, modest gains in utilization, project execution, and staffing efficiency can have meaningful impact on earnings because it is a labor-intensive business.
Improve commercial mix and award quality.Fortrea has emphasized being more selective about the work it pursues. That implies a focus on contract discipline, better fit between customer needs and Fortrea’s capabilities, and a preference for business that supports stronger margins and more predictable execution. For investors, this matters because a CRO can grow revenue while destroying economics if it wins the wrong work on weak terms.
Deepen strategic relationships with sponsors.Fortrea continues to pursue broader sponsor relationships, including larger multi-study programs and FSP arrangements. These relationships can improve visibility, smooth staffing, and raise switching costs. They also allow Fortrea to cross-sell more specialized capabilities into accounts that may initially start with one function or one study.
Use technology and operating analytics to improve delivery.Fortrea’s public materials point to digital and data-enabled trial execution as an important enabler. The practical goal is not to become a software company. It is to reduce cycle times, improve visibility into enrollment and site performance, and make study delivery more consistent for sponsors.
Strengthen cash generation and balance-sheet flexibility.Given the debt structure established at the spin, management has also focused on working capital, cash flow, and balance-sheet improvement. That is strategic, not purely financial, because better cash generation gives the company room to invest in systems, talent, and customer delivery while reducing execution risk.

3. What Is the Business Model of Fortrea?

What customers actually buy

Fortrea sells outsourced clinical-development execution. Sponsors buy project management, scientific and regulatory expertise, operational scale, and access to trained clinical personnel. They may buy an entire trial program on a full-service basis, a discrete early-phase project, or dedicated functional teams under an FSP model.

Recurring or repeat-driven versus one-time

Individual studies are finite, but the business is strongly repeat-driven. Revenue is usually recognized as work is performed over the life of a study, which can span many quarters or several years. Sponsors that trust a CRO often award additional studies, new geographies, or adjacent functional work. FSP relationships can look more recurring than one-off trial awards because they embed personnel or teams into the sponsor’s operating model.

How pricing power works

Fortrea’s pricing power is real but uneven. It is stronger where the work is complex, timelines are critical, specialized talent is scarce, or switching costs are high. It is weaker in more standardized work or where customers run broad competitive RFP processes. Contract terms, change-order discipline, and sponsor fit matter as much as headline price because trial scope often changes after award.

Why the business mix matters

Mix matters because not all CRO revenue is equally attractive. FSP work can provide steadier utilization but may carry different economics than full-service trial management. Large global studies can bring sizable revenue but also execution risk. Early-phase and specialized capabilities may be smaller in absolute dollars but can be strategically valuable because they deepen sponsor relationships and differentiate the platform.

What drives gross margin, operating margin, and cash generation

The main drivers are staff utilization, labor mix, study execution quality, contract discipline, subcontractor management, and overhead control. A service business like Fortrea can lose margin when it carries bench time, underestimates project complexity, absorbs protocol changes without pricing them appropriately, or runs too much transitional overhead after a carve-out. Cash generation depends heavily on billing milestones, collections, working capital discipline, and how quickly backlog converts into revenue and cash. Relative to an asset-heavy manufacturer, Fortrea’s capital expenditures are less important than utilization and receivables management.

Revenue model

Fortrea’s revenue model is primarily fee-for-service. That can include project-based contracts, milestone-based billing, time-and-materials elements, FSP arrangements, and reimbursable pass-through costs for items such as investigator grants or third-party trial expenses. It is not a subscription business. The closest thing to recurring revenue comes from long-duration programs, multi-study sponsor relationships, and embedded functional staffing.

4. What Products and/or Services Does Fortrea Sell?

Fortrea sells services rather than physical products. Its offerings are centered on outsourced clinical development.

Full-service clinical development.This is the core CRO offering: planning and running clinical trials across Phases I-IV, including study start-up, site management, monitoring, data management, biostatistics, medical writing, safety, and closeout activities.
Clinical pharmacology and early-phase services.These services support first-in-human and other early development work. They are important because early-phase programs can establish long-term sponsor relationships and feed downstream trial activity.
Functional Service Provider solutions.Under FSP models, sponsors buy dedicated personnel or teams in functions such as clinical operations, biometrics, safety, or data management. This is often attractive to customers that want outsourced capacity but more direct operational control.
Biometrics, safety, and regulatory support.These capabilities include data management, biostatistics, statistical programming, pharmacovigilance, medical writing, and regulatory support. They are essential to study quality, submission readiness, and customer confidence.
Specialty clinical support.Fortrea also supports areas such as patient recruitment and retention support, as well as clinical development work for medical device and diagnostics customers.

From an economic standpoint, the revenue center of gravity likely sits in full-service clinical development and FSP work, because those offerings involve large teams and multi-quarter delivery. Early-phase clinical pharmacology may be smaller in total revenue but strategically important because it can anchor sponsors earlier in the drug-development lifecycle. That final point is an inference based on typical CRO economics and Fortrea’s service mix.

5. What Are the Key Competitors or Peers of Fortrea?

Fortrea competes in a crowded CRO market. The competitive set varies by sponsor size, therapeutic area, geography, and whether the work is full-service or functional outsourcing. The most relevant direct competitors and close peers include the following.

IQVIA — The largest data-enabled CRO peer, with broad global scale, technology assets, and strong real-world data capabilities.
ICON plc — A large global CRO with full-service clinical development capabilities and broad therapeutic coverage.
PPD, part of Thermo Fisher Scientific — A major CRO platform backed by Thermo Fisher’s broader life-sciences infrastructure and customer relationships.
Medpace — A focused CRO often associated with disciplined execution and strong positioning with biotech and mid-sized sponsors.
Parexel — A large private CRO with strength in clinical development, regulatory services, and market-access-related capabilities.
Syneos Health — A private peer with CRO capabilities and a history of integrated biopharma services, including functional outsourcing.
Worldwide Clinical Trials — A private CRO with meaningful presence in specialty therapeutic areas and global trial execution.
WuXi AppTec / WuXi Clinical-related offerings — A China-rooted global R&D services competitor that can overlap in clinical development support, especially for sponsors seeking broader outsourced development capabilities.

Fortrea also faces competition from smaller specialty CROs, site networks, and sponsor insourcing. In some cases, the real substitute is not another large CRO but a sponsor choosing to keep more operational work in-house.

6. What Is the Marketing Strategy of Fortrea?

Fortrea’s marketing strategy is primarily business-to-business and relationship-led. This is not a consumer brand business. Marketing exists mainly to build credibility with sponsor decision-makers, support account teams, and reinforce the company’s positioning as a focused clinical-development partner.

In practice, that means Fortrea leans more on account-based marketing, scientific thought leadership, industry conferences, publications, case studies, and targeted digital content than on broad brand advertising. A CRO wins work through trust, expertise, references, and proposal quality. That makes marketing a supporting capability to sales and delivery rather than the main engine of demand.

The 2023 separation from Labcorp gave marketing an additional task: establish the Fortrea brand independently of the legacy Labcorp Drug Development and Covance identities. That brand-building challenge is important because many buyers knew the underlying capabilities before they knew the Fortrea name. So Fortrea’s marketing strategy has likely included both reputation transfer from legacy relationships and the creation of a clearer standalone identity.

7. What Are the Key Customer Segments of Fortrea?

Fortrea’s customers are primarily institutional buyers in life sciences. The most important customer segments are:

Large pharmaceutical companies.These customers matter because they can award large, multi-country programs and broader FSP relationships. They also tend to value global scale, compliance infrastructure, and therapeutic depth.
Mid-sized and emerging biotechnology companies.Biotech sponsors are an important source of growth and innovation-driven demand. They often outsource more because they have less internal infrastructure, but they can also be more sensitive to capital-market and funding conditions.
Medical device and diagnostics companies.These customers need evidence generation, clinical operations, and regulatory support tailored to device and diagnostics development pathways.
Specialty and smaller innovators.This includes companies running narrower or more focused clinical programs where speed, flexibility, and technical support can matter more than sheer scale.

Fortrea is not a consumer-facing business and is not sold mainly through distributors. Economically, the company is diversified across sponsor types, but it remains exposed to the overall level and mix of biopharma R&D spending. In particular, weaker biotech funding environments can affect award volumes and study starts across the CRO industry.

8. What Is the Sales Model of Fortrea?

Fortrea sells directly to sponsors through enterprise business-development teams, strategic account managers, therapeutic experts, and solution specialists. The go-to-market model is consultative rather than transactional.

Direct enterprise sales.Fortrea typically competes through RFPs, negotiated proposals, master service agreements, preferred-provider discussions, and FSP opportunities. There is no meaningful distributor or retail channel.
Account-led growth.Large sponsor relationships matter disproportionately because one good relationship can generate multiple studies, geographies, and functional workstreams. That makes customer intimacy and delivery reputation central to sales productivity.
Cross-selling across the development lifecycle.A sponsor may start with an early-phase project, a biometrics assignment, or a staffing need and then expand into broader study execution. That makes the breadth of Fortrea’s platform commercially important.
Long sales cycles and backlog visibility.Deals can take time to win and may turn into backlog before they become revenue. This channel structure supports visibility but also means growth can lag changes in bookings.

The sales model affects pricing and consultant opportunities in a straightforward way: better proposal discipline, stronger account planning, and more precise resource forecasting can improve both win rates and profitability.

9. In What Geographies Does Fortrea Operate?

Fortrea operates globally, with activity spanning North America, Europe, Asia-Pacific, Latin America, and other clinical-research markets. Because it is a CRO, its footprint is defined more by offices, delivery centers, clinical pharmacology capabilities, and networks of investigators and sites than by factories or warehouses.

North America is strategically important because it includes Fortrea’s headquarters in Durham, North Carolina and a large base of pharma, biotech, and med-tech customers. Europe is also important both as a sponsor market and as a region for multi-country clinical operations. Asia-Pacific matters for both delivery capacity and access to patients and investigators in global studies. Latin America and other emerging research markets can be important for enrollment and geographic diversity in trials.

Fortrea’s operational geography therefore has two layers. One is where Fortrea has employees, offices, and systems. The other is where sponsors need studies executed through local sites, investigators, and regulatory processes. A global CRO has to manage both.

10. Who Are the Owners of Fortrea?

Fortrea is a publicly traded company listed under the ticker FTRE. It became an independent company through Labcorp’s 2023 spin-off of its clinical development business. Since that separation, Fortrea has had a public-market ownership structure rather than a controlling corporate parent. As of the latest publicly available ownership disclosures, Fortrea does not appear to have a publicly disclosed controlling shareholder; ownership is primarily institutional and widely distributed among public shareholders.

11. How Is Fortrea Organized?

Fortrea reports one operating and reportable segment, which simplifies external reporting. Internally, however, the company is best understood as a global services platform organized around capabilities, customers, and regions rather than around distinct product divisions.

Listed parent and global subsidiaries.Fortrea Holdings Inc. is the public parent of a multinational operating structure that contracts with customers and employs staff across multiple jurisdictions.
Service-line organization.Operationally, Fortrea appears to be run around major capability areas such as full-service clinical development, early-phase work, FSP delivery, biometrics, safety, and related specialist functions.
Regional and country execution.Clinical research requires local regulatory, site, and patient access capabilities, so country- and region-level operations remain important even within a single reportable segment.
Central corporate functions.As a post-spin company, Fortrea has had to build or expand standalone functions in finance, HR, legal, procurement, IT, cybersecurity, and compliance.

The key point is that Fortrea reports as one segment, but the economics of the business still vary by service model, customer type, and geography.

12. How Does Fortrea Operate?

Fortrea operates by orchestrating the many moving parts of clinical development on behalf of sponsors. Day to day, that means managing people, data, sites, and timelines rather than manufacturing products.

Win and scope the work.The process starts with sponsor discussions, protocol understanding, feasibility assessments, pricing, and contract negotiation.
Set up the study.Fortrea then helps with study start-up activities such as regulatory submissions, site identification, contracting, investigator onboarding, and operational planning.
Execute trial delivery.This includes monitoring sites, coordinating investigators, managing enrollment, handling data flows, and ensuring protocol compliance.
Run biometrics and safety processes.Data management, biostatistics, pharmacovigilance, medical writing, and quality oversight are central to turning operational activity into usable clinical evidence.
Coordinate external vendors and sites.A CRO often manages a network that can include laboratories, imaging providers, technology vendors, couriers, and patient-facing service partners. Vendor management is therefore part of core operations, not an afterthought.
Close out and support reporting.At the end of a trial, Fortrea helps drive database lock, analysis support, reporting, and study closeout.

The main operational bottlenecks are familiar across the CRO industry: site activation speed, patient enrollment, protocol amendments, staffing continuity, subcontractor coordination, and sponsor decision latency. For Fortrea specifically, post-spin systems migration and organizational simplification have added another layer of complexity to execution.

13. What Are the Growth Opportunities for Fortrea?

Fortrea’s most plausible growth opportunities come from a mix of market expansion and self-help.

Management-visible growth opportunities

Winning more high-quality awards. Better customer selection, contract discipline, and delivery performance can improve both revenue quality and margin quality.
Expanding strategic account relationships. Larger pharma and biotech relationships can create repeat business, broader study awards, and deeper FSP penetration.
Cross-selling across service lines. Early-phase work, specialty services, and functional support can lead to broader full-service clinical-development assignments.
Using technology and analytics to improve execution. Faster start-up, better resource planning, and stronger project controls can support growth indirectly by improving win rates and customer retention.
Improving the standalone operating model. Some of Fortrea’s near-term upside comes not from entering new markets but from reducing carve-out friction and making the existing platform more productive.

Reasonable external synthesis

Higher outsourcing penetration in drug development. Biopharma companies continue to rely heavily on CROs, especially when they want flexibility, global reach, or specialized talent.
Recovery in biotech funding. If financing conditions for biotech improve, award activity and project starts can improve across the sector.
Complex trial categories. Oncology, rare disease, and other more complex trial types can favor established global operators with strong coordination capabilities.
Geographic expansion within global studies. Sponsors increasingly need multi-region execution, which can benefit CROs with broad operational reach.

Main constraints

Pricing pressure in competitive bids
Biotech funding volatility
Clinical-talent retention and wage inflation
Execution risk during system and process separation from Labcorp
Debt and cash-flow discipline limiting strategic flexibility

For Fortrea, the most credible near-term growth may come as much from better execution and mix improvement as from simple end-market tailwinds.

14. What Is the History of Fortrea?

Fortrea is a young independent company with older operating roots. The business history is easiest to understand in four steps.

Legacy roots. The platform that became Fortrea was built within the broader clinical development business associated with Covance and later Labcorp.
2015 Labcorp-Covance combination. Labcorp acquired Covance in 2015, creating a larger organization that combined diagnostics capabilities with drug-development services.
2023 spin-off. Labcorp separated its clinical development business in 2023, creating Fortrea as an independent public company.
Post-spin transition. Since independence, Fortrea’s history has been defined less by acquisitions and more by separation work: building standalone systems, establishing the Fortrea brand, tightening customer and contract mix, and improving profitability as a carve-out becomes a self-sufficient company.

Fortrea therefore does not yet have a long standalone M&A history of its own. The more important historical fact is that its operating capabilities are much older than its stock-market life.

15. What Are the Key Suppliers to Fortrea?

Suppliers matter to Fortrea, although in a CRO the supplier base looks more like a delivery ecosystem than a classic manufacturing supply chain. The most important supplier categories include:

Investigator sites and principal investigators.These are not suppliers in the factory sense, but they are essential operating partners. Site quality, responsiveness, and patient access directly affect enrollment speed and study timelines.
Laboratories and specialty testing providers.Clinical trials often require central lab and specialty testing support. Labcorp is especially notable because Fortrea disclosed transition and commercial arrangements with its former parent after the spin, making Labcorp an important counterparty rather than simply a former owner.
Imaging, cardiac-safety, and other specialist vendors.Complex studies often rely on third-party providers for niche endpoints and technical services.
Technology vendors.Clinical-trial platforms, data systems, enterprise software, cloud infrastructure, and cybersecurity tools are central to both delivery and compliance.
Travel, logistics, and patient-support partners.These vendors help with site support, shipments, and patient-facing trial logistics in global studies.

Supplier structure matters strategically because Fortrea is ultimately judged by sponsors on timelines, quality, and data integrity, even when third parties perform part of the work. That makes vendor governance a core management discipline.

16. What Is the Technology Strategy of Fortrea?

Fortrea’s technology strategy is best viewed as an execution strategy. The company is not primarily selling software; it is using technology to run trials better and to operate independently after the spin.

Build standalone enterprise systems.Since 2023, one major technology priority has been reducing dependence on Labcorp transition arrangements and establishing Fortrea’s own finance, HR, procurement, operational, and reporting systems.
Support digital trial execution.Like other modern CROs, Fortrea depends on clinical-trial management systems, electronic data capture, trial master file workflows, safety systems, and operational dashboards. These tools help coordinate studies and give sponsors visibility.
Improve analytics and operational control.Technology can improve site selection, enrollment forecasting, monitor productivity, project profitability, and quality oversight. In a services business, better data can translate directly into better margins and customer satisfaction.
Protect regulated data.Because Fortrea handles sensitive clinical and patient-related information, cybersecurity, system validation, data governance, and compliance are strategic necessities, not just IT hygiene.

Technology is therefore both an internal enabler and part of the sponsor value proposition. The near-term challenge is to convert post-spin systems work into long-term operational advantage.

17. What Is the Talent Strategy of Fortrea?

Fortrea is fundamentally a talent business. Its most important assets walk out the door every evening: clinical research associates, project managers, physicians, nurses, biostatisticians, programmers, pharmacovigilance professionals, regulatory specialists, and account leaders.

Recruit and retain scarce clinical talent.Public CRO filings consistently show that talent availability is a core operating risk. Fortrea needs enough qualified people, in the right regions and therapeutic areas, to staff studies on time.
Use global delivery effectively.The company’s labor model likely depends on balancing local clinical expertise with more scalable regional or global delivery hubs for functions such as biometrics, data management, and back-office support.
Maintain training and compliance standards.Clinical development is regulated work. Training in Good Clinical Practice, quality procedures, documentation, and sponsor-specific requirements is part of the delivery engine.
Build a standalone culture and employer brand.Since the Labcorp separation, Fortrea has also had to define itself as an independent employer, not just as a legacy business unit inside a larger company.

Talent is both competitive advantage and constraint. Higher attrition or poor utilization can hurt margins quickly, while strong staffing continuity can improve customer trust and repeat business.

18. What Is the Finance Strategy of Fortrea?

Fortrea’s finance strategy since the spin has been shaped by three realities: it is a newly independent public company, it carries debt established in connection with the separation, and it operates in a labor-intensive service business where cash conversion depends heavily on execution and working capital.

Deleveraging and liquidity discipline.Fortrea’s public commentary has emphasized cash generation and balance-sheet flexibility. That is logical for a carve-out that began life with meaningful financial obligations.
Margin recovery.Finance strategy is closely linked to operating strategy. Improving utilization, reducing stranded costs, tightening contract economics, and simplifying the organization are all financial levers as well as operating ones.
Working capital improvement.Billing milestones, collections, change orders, and receivables management matter more to a CRO than heavy factory capex. For Fortrea, cash discipline is a daily operating issue.
Selective reinvestment rather than broad shareholder payouts.At this stage, the more likely uses of capital are systems independence, capability investment, and debt reduction rather than aggressive dividends or buybacks.

In short, Fortrea’s finance strategy appears designed to support a transition from carve-out complexity toward a steadier, more self-funding CRO model.

19. How Companies Like Fortrea Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of over 8,000 independent management consultants who are based in more than 50 countries. These consultants are alums of McKinsey, Bain, BCG, and other top consulting firms. Companies like Fortrea engage Umbrex when they need talent with the training these top global firms provide but they do not need a full team with all the overhead. Umbrex has consultants across Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI. For a company like Fortrea, the most relevant projects would usually be tightly scoped, execution-oriented, and tied to the company’s post-spin priorities.

Post-spin operating model redesign: redesign decision rights, shared services, and governance as Fortrea completes separation from Labcorp.
TSA exit and separation PMO support: manage milestone tracking, issue escalation, and risk reduction across finance, HR, procurement, and IT migrations.
Customer and contract profitability analytics: assess which sponsor relationships, service lines, and study types create the strongest returns and where pricing discipline needs improvement.
Strategic account growth planning: build account plans for large pharma and biotech clients, including cross-sell strategies across full-service, FSP, and early-phase offerings.
Clinical trial delivery productivity transformation: improve site start-up, enrollment performance, monitor utilization, and project controls.
Vendor and partner strategy: optimize the ecosystem of labs, imaging providers, technology vendors, and other specialist suppliers that support trial delivery.
Working-capital and cash improvement: redesign billing, change-order capture, collections, and backlog-to-cash processes.
Technology roadmap and systems integration: prioritize enterprise systems, eClinical tools, data architecture, and operating dashboards needed for a stronger standalone platform.
Global footprint and talent-location strategy: evaluate where Fortrea should place biometrics, data-management, finance, and other roles for quality, cost, and resilience.
AI use-case prioritization: identify practical AI applications in proposal generation, document quality control, protocol feasibility, knowledge management, and operational reporting.